Omeros Corporation announced on September 2, 2025, the publication of a peer-reviewed manuscript in the American Journal of Hematology. The manuscript details survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab.
The data presented in the publication originated from a global expanded access program (EAP) for narsoplimab. Narsoplimab, which inhibits MASP-2, the effector enzyme of the lectin pathway of complement, is currently under review for marketing authorization.
This peer-reviewed publication provides independent scientific validation of narsoplimab's efficacy in a real-world setting. It reinforces the positive clinical data previously reported and is expected to enhance confidence in the drug among the medical community as it awaits regulatory decisions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.